Abstract
Aims To analyze the role of lncRNA PVT1 in cerebral ischemia-reperfusion (I/R) injury induced by deep hypothermia low flow (DHLF).
Methods and results A total of 72 lncRNAs were differentially expressed in the brain tissue of DHLF mice. PVT1 expression was significantly downregulated in DHLF mouse brain tissue, preoperative and postoperative blood samples from children undergoing DHLF extracorporeal circulation, and hOGD-treated cells. In the mouse model, the DHLF group with PVT1 overexpression had heavier brain tissue damage than the control group; apoptosis rate, reactive oxygen species level and caspase-3 enzyme activity were significantly higher in the lenti-PVT1 group than in the lenti-control group. Compared those in the lenti-control group, the total distance traveled, distance of action in the center, number of entering the center, average speed of walking reduced, and the distance of walking in the periphery and and peripheral walking distance increased in the lenti-PVT1 group. The dual luciferase reporter gene assay verified the possible binding sites between PVT1, miR-148a-3p and MKL1. In the animal model, cellular model, and blood samples of children experiencing DHLF, miR-148a-3p expression increased and MKL1 expression decreased. In experimental studies in vivo and in vitro, PVT1 and MKL1 expression increased, and miR-148a-3p expression decreased. Meanwhile MKL1 inhibitor CCG1423 reversed the apoptosis in neuronal cells.
Conclusion PVT1 may adsorb miR-148a-3p to regulate the expression of MKL1, a downstream gene of miR-148a-3p, a mechanism promoting the apoptosis of neuronal cells in DHLF mice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Natural Science Foundation of China (81970265, 82000303); Nanjing Science and Technology Development Project (2019060007); Anhui Provincial Natural Science Foundation (2208085QH230).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent was obtained from the legal guardian of the children, and the protocol was approved by the Institutional Ethics Committee of Children's Hospital of Nanjing Medical University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest with the contents of this article.
Data Availability
All data mentioned in the manuscript are original.
